The thiols glutathione, cysteine, and homocysteine in human immunodeficiency virus (HIV) infection

Nutrients and Foods in Aids

Volumn , Issue , 2017, Pages 35-70

  Muller F ^a   Aukrust, P ^a   Svardal, A M ^b   Berge, R K ^b   Ueland, P M ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85054442192     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203745250     Document Type: Chapter

References (218)

1. Buhl, R., Jaffe, H.A., Holroyd, K.J., Wells, F.B., Mastrangeli, A., Saltini, C., Cantin, A.M., and Crystal, R.G., Systemic glutathione deficiency in symptomfree HIV-seropositive individuals, Lancet,2, 1294, 1989.
2. Eck, H.R, Gmünder, H., Hartmann, M., Petzoldt, D., Daniel, V., and Dröge, W., Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-l-infected patients, Biol. Chem. Hoppe-Seyler,370, 101, 1989.
3. Staal, F.J.T., Roederer, M., Israelski, D.M., Bubp J., Mole, L.A., Mcshane, D., Deresinski, S.C., Ross, W., Sussman, H., Raju, P. A., Anderson, M.T., Moore, W., Ela, S.W., and Herzenberg, L.A., Intracellular glutathione levels in T-Cell subsets decrease in HIV-infected individuals, AIDS Res. Hum. Retroviruses,8, 305, 1992.
4. Roederer, M., Staal, F.J.T., Osada, H., and Herzenberg, L.A., CD4 and CD8 T Cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses, Int. Immunol,3, 933, 1991.
5. Aukrust, P., Svardal, A.M., Müller, F., Lunden, B., Ueland, P.M., and Froland, S.S., Increased levels of oxidized glutathione in CD4+ lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection, Blood,86, 258, 1995.
6. Roederer, M., Ela, S.W., Staal, F.J.T., and Herzenberg, L.A., N-Acetylcysteine — Anew approach to anti-HIV therapy, AIDS Res. Hum Retroviruses,8, 209, 1992.
7. Müller, F., Reactive oxygen intermediates and human immunodeficiency virus (HIV) infection, Free Radical Biol. Med.,13, 651, 1992.
8. Dröge, W., Cysteine and glutathione deficiency in AIDS patients — a rationale for the treatment with N-acetyl-cysteine, Pharmacology,46, 61, 1993.
9. Halliwell, B. and Cross, C.E., Reactive oxygen species, antioxidants, and acquired immunodeficiency syndrome. Sense or speculation, Arch. Intern. Med., 151, 29, 1991.
10. Halliwell, B. and Gutteridge, J.M.C., Role of free radicals and catalytic metal ions in human disease: an overview, Methods Enzymol.,186, 1, 1990.
11. de Bono, D.R, Free radicals and antioxydants in vascular biology: the roles of reaction kinetics, environment and substrate turnover, Q.J. Med.,87, 445, 1994.
12. Bast, A., Haenen, G.R.M.M., and Doelman, C.J.A., Oxidants and antioxidants: state of art, Atn. J. Med.,91, 4S, 1991.
13. Halliwell, B., Drug antioxidant effects, Drug,42, 569, 1991.
14. Yu, B.R, Cellular defenses against damage from reactive oxygen species, Physiol. Rev.,74, 139, 1994.
15. Rosen, G.M., Pou, S.P., Ramos, C.L., Cohen, M.S., and Britigan, B.E., Free radicals and phagocytic cells, FASEB J., 9, 200, 1995.
16. Halliwell, B., Reactive oxygen species in living systems — source, biochemistry, and role in human disease, Am. J. Med.,91(suppl. 3C), 14S, 1991.
17. Ames, B.N., Shigenaga, M.K., and Hagen, T.M., Oxidants, antioxidants, and the degenerative diseases of aging, Proc. Natl. Acad. Sci. U.S.A.,90, 7915,1993.
18. Frei, B., Reactive oxygen species and antioxidant vitamins: mechanism of action, Am. J. Med.,97, 5S, 1994.
19. Sinclair, A.J., Barnett, A.H., and Lunec, J., Free radicals and antioxidant systems in health and disease, Br. J. Hosp. Med.,43, 334, 1990.
20. Meister, A., Glutathione ascorbic acid antioxidant system in animals, J. Biol. Chem.,269, 9397, 1994.
21. Meister, A., On the antioxidant effects of ascorbic acid and glutathione, Bio-chem. Pharm.,44, 1905, 1992.
22. Jain, A., Martensson, J., Mehta, T., Krauss, A.N., Auld, P.A.M., and Meister, A., Ascorbic acid prevents oxidative stress in glutathione-deficient mice: effects on lung type II cell lamellar bodies, lung surfactant, and skeletal muscle, Proc. Natl. Acad. Sci. U.S.A.,89, 5093, 1992.
23. Packer, L., New horizons in vitamin E research — the vitamin E cycle, biochemistry, and clinical applications. In Lipid Soluble Antioxidants: Biochemistry and Clinical Applications, Ong, A.S.H. and Packer, L., Eds., Birkhäuser Verlag, Basel, 1-16, 1992.
24. Packer, L., Witt, E.H., and Tritschler, H.J., Alpha-lipoic acid as a biological antioxidant, Free Radical. Biol. Med.,19, 227, 1995.
25. Han, D., Tritschler, H.J., and Packer, L., Alpha-lipoic acid increases intracellular glutathione in a human T-lymphocyte Jurkat cell line, Biochem. Biophys. Res. Commun.,207, 258, 1995.
26. Meister, A., Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmac. Ther.,51, 155, 1991.
27. Deneke, S.M. and Fanburg, B.L., Regulation of cellular glutathione, Am. J. Physiol,257, L163, 1989.
28. Meister, A., Glutathione metabolism and its selective modification, J. Biol. Chem.,263, 17206, 1988.
29. Thompson, G.A. and Meister, A., Utilization of L-cystine by the gamma-glutamyl transpeptidase gamma-glutamyl cyclotransferase pathway, Proc. Natl. Acad. Sci. U.S.A.,72, 1985, 1975.
30. Meister, A., Glutathione, ascorbate, and cellular protection, Cancer Res., 54(suppl.), 1969S, 1994.
31. Meister, A. and Anderson, M.E., Glutathione, Annu. Rev. Biochem.,52, 711, 1983.
32. Kang, S.-S., Wong, P.W.K., and Malinow, M.R., Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease, Annu. Rev. Nutr.,12, 279, 1992.
33. Boushey, C.J., Beresford, S.A., Omenn, G.S., and Motulsky, A.G., A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes, JAMA,274, 1049, 1995.
34. Ueland, P.M., Refsum, H., Stabler, S.P., Malinow, M.R., Andersson, A., and Allen, R.H., Total homocysteine in plasma or serum. Methods and clinical applications, Clin. Chem.,39, 1764, 1993.
35. Wall, R.T., Harlan, J.M., Harker, L.A., and Striker, G.E., Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury, Thrombosis Res.,18, 113, 1980.
36. Starkebaum, G. and Harlan, J.M., Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine, J. Clin. Invest.,77, 1370, 1986.
37. Preibisch, G., Kiiffner, C., and Elstner, E.F., Biochemical model reactions on the prooxidative activity of homocysteine, Z. Naturforsch,48c, 58, 1993.
38. Mansoor, M.A., Bergmark, C., Svardal, A.M., Lonning, P.E., and Ueland, P.M., Redox status and protein binding of plasma homocysteine and other ami-nothiols in patients with early-onset peripheral vascular disease, Arterioscler. Thromb. Vase. Biol,15, 232, 1995.
39. Ueland, P.M. and Refsum, H., Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and therapy, J. Lab. Clin. Med.,114, 473, 1989.
40. Lunec, J. Free radicals: their involvement in disease processes, Ann. Clin. Biochem.,27, 173, 1990.
41. Halliwell, B., Gutteridge, J.M.C., and Ross, C.E., Free radicals, antioxidants, and human disease: where are we now? J. Lab. Clin. Med.,119, 598, 1992.
42. Floyd, R.A., Role of oxygen free radicals in carcinogenesis and brain ischemia, FASEB J., 4, 2587, 1990.
43. Cross, C.E., van der Vliet, A., ONeill, C.A., and Eiserich, J.P., Reactive oxygen species and the lung, Lancet,344, 930, 1994.
44. Sen, C.K. and Packer, L., Antioxidant and redox regulation of gene transcrip-tionn, FASEB J.,10, 709, 1996.
45. Schraufstatter, I.U., Hyslop, P.A., Hinshaw, D.B., Spragg, R.G., Sklar, R.A., and Cochrane, C.G., Hydrogen peroxide-induced injury of cells and its prevention by inhibitors of poly (ADB-ribose) polymerase, Proc. Natl. Acad. Sci. U.S.A., 83, 4908, 1986.
46. 2+ dependent pore activitated by oxidative stress in heart mitochondria, Biochem. J.,245, 915, 1987.
47. Sandstrom, P.A., Tebbey, P.W., van Cleave, S., and Buttke, T. M., Lipid hydroperoxides induce apoptosis in T cells displaying a HIV associated glutathione peroxidase deficiency, J. Biol. Chem.,269, 798, 1994.
48. Walker, M.W., Kinter, M.T., Roberts, R.J., and Spitz, D.R., Nitric oxide-induced cytotoxicity: involvement of cellular resistance to oxidative stress and the role of glutathione in protection, Pediatr. Res.,37, 41, 1995.
49. de Quay, B., Malinverni, R., and Lauterburg, B.H., Glutathione depletion in HIV-infected patients — role of cysteine deficiency and effect of oral N-ace-tylcysteine, AIDS,6, 815, 1992.
50. Pirmohamed, M., Williams, D., Tingle, M.D., Barry, M., Khoo, S.H., OMahony, C., Wilkins, E.G.L., Breckenridge, A.M., and Park, B.K., Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency, AIDS,10, 501, 1996.
51. Dröge, W., Eck, H.P., and Mihm, S., HIV-induced cysteine deficiency and T-cell dysfunction — a rationale for treatment with N-acety Icy steine, Immunol. Today,13, 211, 1992.
52. Jacobsen, D.W., Green, R., Herbert, V., Longworth, D.L, and Rehm, S., Decreased serum glutathione with normal cysteine and homocysteine levels in patients with AIDS, Clin. Res.,38, 556A, 1990.
53. Ubbink, J.B., Vermaak, W.J.H., van der Merwe, A., and Becker, P.J., The effect of blood sample aging and food consumption on plasma total homocysteine levels, Clin. Chim. Acta,207, 119, 1992.
54. Hum, S., Koski, K.G., and Hoffer, L.J., Varied protein intake alters glutathione metabolism in rats, J. Nutr.,122, 2010, 1992.
55. Lang, C.A., Naryshkin, S., Schneider, D.L., Mills, B.J., and Lindeman, R.D., Low blood glutathione levels in healthy aging adults, J. Lab. Clin. Med.,120, 720,1992.
56. Mansoor, M.A., Svardal, A.M., and Ueland, P.M., Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma, Anal. Biochem.,200, 218, 1992.
57. Duthie, G.G., Arthur, J.R., and James, W.P., Effects of smoking and vitamin E on blood antioxidant status, Am. J. Clin. Nutr.,53, 1061S, 1991.
58. Smaland, R., Svardal, A.M., Lote, K., Ueland, P.M., and Laerum, O.D., Glutathione content in human bone marrow and circadian stage relation to DNA synthesis, J. Natl. Cancer Inst.,83, 1092, 1991.
59. Farooqui, M.Y.H. and Ahmed, A.E., Circadian periodicity of tissue glutathione and its relationship with lipid peroxidation in rats, Life Sei.,34, 2413, 1984.
60. Svardal, A.M., Mansoor, M.A., and Ueland, P.M., Determination of reduced oxidized, and protein-bound glutathione in human plasma with precolumn derivatization with monobromobimane and liquid chromatography, Anal. Biochem.,184, 338, 1990.
61. Munday, R., Toxicity of thiols and disulphides: involvement of free-radical species, Free Radical Biol. Med.,7, 659, 1989.
62. Miiller, F, Svardal, A.M., Aukrust, P., Berge, R.K., Ueland, P.M., and Froland, S.S., Elevated plasma concentration of reduced homocysteine in patients with human immunodeficiency virus infection, Am. J. Clin. Nutr.,63, 242, 1996.
63. Eck, H.P., Mertens, T., Rosokat, H., Fatkenheuer, G., Pohl, C., Schrappe, M., Daniel, V., Naher, H., Petzoldt, D., Drings, P., et al., T4+ cell numbers are correlated with plasma glutamate and cystine levels: association of hyper-glutamataemia with immunodeficiency in diseases with different aetiologies, Int. Immunol.,4, 7, 1992.
64. Hortin, G., Landt, M., and Powderly, W.G., Changes in plasma amino acid concentrations in response to HIV-1, Clin. Chem.,40, 785, 1994.
65. Fiskerstrand, T., Refsum, H., Kvalheim, G., and Ueland, P.M., Homocysteine and other thiols in plasma and urine: automated determination and sample stability, Clin. Chem.,39, 263, 1993.
66. van der Ven, A.J.A.M., Mier, P., Peters, W.H.M., Dolstra, H., van Erp, P.E.J., Koopmans, P.P., and van der Meer, J.W., Monochlorobimane does not selectively label glutathione in peripheral blood mononuclear cells, Anal. Biochem., 217, 41, 1994.
67. Cayota, A., Vuillier, F., Gonzalez, G., and Dighiero, G., In vitro antioxidant treatment recovers proliferative responses of anergic CD4+ lymphocytes from human immunodeficiency virus-infected individuals, Blood,87, 4746, 1996.
68. Kavanagh, T.J., Grossmann, A., Jaecks, E.P., Jinneman, J.C., Eaton, D.L, Martin, G.M., and Rabinovitch, P.S., Proliferative capacity of human peripheral blood lymphocytes sorted on basis of glutathione content, J. Cell. Physiol.,145, 472, 1990.
69. Aukrust, P., Svardal, A.M., Müller, F., Lunden, B., Berge, R.K., and Frøland, S.S., Decreased levels of total and reduced glutathione in CD4(+) lymphocytes in common variable immunodeficiency are associated with activation of the tumor necrosis factor system: possible immunopathogenic role of oxidative stress, Blood,86, 1383, 1995.
70. Aukrust, P., Svardal, A.M., Müller, F., Lunden, B., Nordoy, I., and Frøland, S.S., Markedly disturbed glutathione redox status in CD45RA+CD4+ lymphocytes in human immunodeficiency virus type 1 infection is associated with selective depletion of this lymphocyte subset, Blood,88, 2626, 1996.
71. Barditch-Crovo, P., Svobodova, V., and Lietman, P., Apparent deficiency of glutathionine in the PBMCs of people with AIDS depends on method of expression, J. Acq. Immun. Defic. Synd. Hum. R.,8, 313, 1995.
72. Staal, F.J.T., Ela, S.W., Roederer, M., Anderson, M.T., and Herzenberg, L.A., Glutathione deficiency and human immunodeficiency virus infection, Lancet, 339, 909, 1992.
73. Jenkinson, S.G., Lawrence, R.A., Zamora, C.A., and Deneke, S.M., Reduction of intracellular glutathione in alveolar type II pneumocytes following BCNU exposure, Am. J. Physiol.,266, L125, 1994.
74. Miura, K. Ishii, T., Sugita, Y., and Bannai, S., Cystine uptake and glutathione level in endothelial cells exposed to oxidative stress, Am. J. Physiol.,262, C50, 1992.
75. Cantin, A.M., North, S.L., Hubbard, R.C., and Crystal, R.G., Normal alveolar epithelial lining fluid contains high levels of glutathione, J. Appl. Physiol.,63, 152, 1987.
76. Shi, M.M., Iwamoto, T., and Forman, H.J., Gamma-glutamylcysteine synthetase and GSH increase in quinone-induced oxidative stress in BPAEC, Am. J. Physiol.,267, L414, 1994.
77. Benard, O. and Balasubramanian, K.A., Effect of oxidant exposure on thiol status in the intestinal mucosa, Biochem. Pharmacol.,45, 2011, 1993.
78. Harris, E.D., Regulation of antioxidant enzymes, FASEB J.,6, 2675, 1992.
79. Suttorp, N., Kästle, S., and Neuhof, H., Glutathione redox cycle is an important defense system of endothelial cells against chronic hyperoxia, Lung,169, 203, 1991.
80. Irita, K., Okabe, H., Koga, A., Kurosawa, K., Tagawa, K., Yamakawa, M., Yoshitake, J.-L, and Takahashi, S., Increased sinusidal efflux of reduced and oxidized glutathione in rats with endotoxin/D-galactosamine hepatitis, Circ. Shock,42, 115, 1994.
81. Hughes, H.H., Jaeschke, H., and Mitchell, J.R., Measurement of oxidative stressin vivo, Methods Enzymol.,186, 681, 1990.
82. Garcia de la Asuncion, J., Millan, A., Pia, R., Bruseghini, L., Esteras, A., Pallardo, F.V., Sastre J, and Vina, J., Mitochondrial glutathione oxidation correlates with age-associated oxidative damage to mitochondrial DNA, FASEB J., 10, 333, 1996.
83. Hwang, C., Sinskey, A. J., and Lodish, H.F., Oxidized redox state of glutathione in the endoplasmic reticulum, Science,257, 1496, 1992.
84. Dröge, W., Eck, H.P., Näher, H., Pekar, U., and Daniel, V., Abnormal amino acid concentrations in the blood of patients with acquired immunodeficiency syndrome (AIDS) may contribute to the immunological defect, Biol. Chem. Hoppe-Seyler,369, 143, 1988.
85. Parvy, P., Bardet, J., Rabier, D., Gasquet, M., and Kamoon, P., Intra- and interlaboratory quality control for assay of amino acids in biological fluids: 14 years of French experience, Clin. Chem.,39, 1831, 1993.
86. Sato, J., Iwata, S., Nakamura, K., Hori, T., Mori, K., and Yodo, J., Thiol-mediated redox regulation of apoptosis, J. Immunol,154, 3194, 1995.
87. Iwata, S., Hori, T., Sato, N., Uedataniguchi, Y., Yamabe, T., Nakamura, H., Masutani, H., and Yodoi, J., Thiol-mediated redox regulation of lymphocyte proliferation — possible involvement of adult T cell leukemia-derived factor and glutathione in transferrin receptor expression, J. Immunol,152, 5633,1994.
88. Holmgren, A., Thioredoxin and glutaredoxin systems, J. Biol. Chem.,264, 13963, 1989.
89. Newman, G.W., Balcewicz-Salbinska, M.K., Guarnaccia, J.R., Remold, H.G., and Silberstein, D.S., Opposing regulatory effects of thioredoxin and eosinophil cytotoxicity-enhancing factor on the development of human immunodeficiency virus 1, J. Exp. Med.,180, 359, 1994.
90. Masutani, H., Naito, M., Takahashi, K., Hattori, T., Koito, A., Takatsuki, K., Go, T., Nakamura, H., Fujii, S., Yoshida, Y., Okuma, M., and Yodor, J., Dysregulation of adult T-cell leukemia-derived factor (ADF)/thioredoxin in HIV infection: loss of ADF high producer cells in lymphoid tissues of AIDS patients, AIDS Res. Hum. Retrovirus.,8, 1707, 1992.
91. Nakamura, H., DeRosa, S., Roederer, M., Anderson, M.T., Dubs, J.G., Yodoi, J., Holmgren, A., and Herzenberg, L.A., Elevation of plasma thioredoxin levels in HIV-infected individuals, Int. Immunol,8, 603, 1996.
92. Macho, A., Castedo, M., Marchetti, P., Aguilar, J.J., Decaudin, D., Zamzami, N., Girard, P.M., Uriel, J., and Kroemer, G., Mitochondrial dysfunctions in circulating T lymphocytes from human immunodeficiency virus-1 carriers, Blood,86, 2481, 1995.
93. Buttke, T.M. and Sandstrom, P.A., Oxidative stress as a mediator of apoptosis, Immunol. Today,15, 7, 1994.
94. 2, J. Clin. Invest.,89, 794, 1992.
95. Chang, S.W., Ohara, N., Kuo, G., and Voelkel, N.F., Tumor necrosis factor-induced lung injury is not mediated by platelet-activating factor, Am J. Physiol., 257, L232, 1989.
96. Mallery, S.R., Bailer, R.T., Hohl, C.M., Ngbautista, C.L., Ness, G.M., Livingston, B.E., Hout, B.L., Stephens, R.E., and Brierley, G.R, Cultured AIDS-related Kaposi's sarcoma (AIDS-KS) cells demonstrate impaired bioenergetic adaptation to oxidant challenge: implication for oxidant stress in AIDS-KS pathogenesis, J. Cell Biochem.,59, 317, 1995.
97. Staal, F.J.T., Roederer, M., Herzenberg, L.A., and Herzenberg, L., Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus, Proc. Natl. Acad. Sci. U.S.A.,87, 9943, 1990.
98. Bilzer, M. and Lauterberg, B.FL, Glutathione metabolism in activated human neutrophils: stimulation of glutathione synthesis and consumption of glutathione by reactive oxygen species, Eur. J. Clin. Invest.,21, 316, 1991.
99. Adamson, G.M. and Billings, R.E., Tumor necrosis factor induced oxidative stress in isolated mouse hepatocytes, Arch. Biochem. Biophys.,294, 223, 1992.
100. Eugul, E.M., deLustro, B., Rouhafza, S., Ilnicka, M., Lee, S.W., Wilhelm, R., and Allison, A.C., Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-α, IL-lβ and IL-6 by human peripheral blood mononuclear cells, Int. Immunol.,6, 409, 1994.
101. Peristeris, P., Clark, B.D., Gatti, S., Faggioni, R., Mantovani, A., Mengozzi, M., Orencole, S.F., Sironi, M., and Ghezzi, P., N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production, Cell. Immunol.,240, 390, 1992.
102. Staal, F.J.T., Anderson, M.T., Staal, G.E.J., Herzenberg, L.A., and Gitler, C., Redox regulation of signal transduction — tyrosine phosphorylation and calcium influx, Proc. Natl. Acad. Sci. U.S.A.,91, 3619, 1994.
103. Hamilos, D.L. and Wedner, H.J., The role of glutathione in lymphocyte activation. I. Comparison of inhibitory effects of buthionine sulfoximine and 2-cyclohexene-l-one by nuclear size formation, J. Immunol.,135, 2740, 1985.
104. Suthanthiran, M., Anderson, M.D., Sharma, V.K., and Meister, A., Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via CD2 and CD3 antigen, Proc. Natl. Acad. Sci. U.S.A.,87, 3343, 1990.
105. Hilly, M., Piétri-Rouxel, F., Coquil, J.-F., Guy, M., and Mauger, J.-P., Thiol reagents increase the affinity of the inositol 1,4,6-triphosphate receptor, J. Biol. Client.,268, 16488, 1993.
106. Dröge, W., Schulze-Osthoff, K., Mihm, S., Gaiter, D., Schenk, H., Eck, H.P., Roth, S., and Gmiinder, H., Functions of glutathione and glutathione disulfide in immunology and immunopathology, FASEB J., 8, 1131, 1994.
107. Ziegler, D.M., Role of reversible oxidation-reduction of enzyme thiol-disul-phides in metabolic regulation, Anmt. Rev. Biochem.,54, 305, 1985.
108. Yamauchi, A. and Bloom, E.T., Requirement of thiol compounds as reducing agents for IL-2 mediated induction of LAK activity and proliferation of human NK cells, J. Immunol.,151, 5535, 1993.
109. Dröge, W., Pottmeyer-Greber, C., Schmidt, H., and Nick, S., Glutathione augments the activation of cytotoxic T lymphocytes in vivo, Immunobiology, 171, 151, 1986.
110. Clerici, M., Via, C.S., Lucey, D.R., Roilides, E., Pizzo, P.A., and Shearer, G.M., Functional dichotomy of CD4+ T-helper lymphocytes in asymptomatic human immunodeficiency virus infection, Eur. J. Immunol.,21, 665, 1991.
111. Clerici, M. and Shearer, G.M., The Thl-Th2 hypothesis of HIV infection: new insights, Immunol. Today,15, 575, 1994.
112. Apostolopoulos, V., Pietersz, G.A., Loveland, B.E., Sandrin, M.S., and McKenzie, I.F., Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses, Proc. Natl. Acad. Sci. U.S.A.,92, 10128, 1995.
113. Jeannin, P., Delneste, Y., Lecoanethenchoz, S., Gauchat, J.F., Life, P., Holmes, D., and Bonnefoy, J.Y., Thiols decrease human interleukin (IL) 4 production and IL-4-induced immunoglobulin synthesis, J. Exp. Med.,182, 1785, 1995.
114. Pantaleo, G. and Fauci, A.S., New concepts in the pathogenesis of HIV infection, Annu. Rev. Immunol.,13, 487, 1995.
115. Clerici, M., Stocks, N.I., Zajac, R.A., Boswell, R.N., Lucey, D.R., Via, C.S., and Shearer, G.M., Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging, J. Clin. Invest.,84, 1892, 1989.
116. Lane, H.C., Depper, J.M., Greene, W.C., Whalen, G., Waldmann, T.A., and Fauci, A.S., Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome: evidence for a selective defect in soluble antigen recognition, N. Engl. J. Med.,313, 79, 1985.
117. Koretzky, G.A., Picus, J., Thomas, M.L., and Weiss, A., Tyrosin phosphatase CD45 is essential for coupling T-cell antigen receptor to the phosphatidyl inositol pathway, Nature,346, 66, 1990.
118. June, C.H., Fletcher, M.C., Ledbetter, J.A., Schieven, G.I., Siegel, J.N., Phillips, A.F., and Samelson, L.E., Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction, Proc. Natl. Acad. Sci. U.S.A.,87, 7722, 1990.
119. lck in T cell signalling and thymocyte development, Adv. Immunol.56, 151, 1994.
120. Weiss, A. and Littman, D.R., Signal transduction by lymphocyte antigen receptors, Cell,76, 263, 1994.
121. Cayota, A., Vuillier, F., Gonzalez, G., and Dighiero, G., CD4(+) lymphocytes from HIV-infected patients display impaired CD45-associated tyrosine phosphatase activity which is enhanced by anti-oxidants, Blood,87, 4746, 1996.
122. Eylar, E., Riveraquinones, C., Molina, C., Baez, I., Molina, F., and Mercado, C.M., N-acetylcysteine enhances T-cell functions and T-cell growth in culture, Int. Immunol.,5, 97, 1993.
123. Wu, D., Meydani, S.N., Sastre, J., Hayek, M., and Meydani, M., In vitro glutathione supplementation enhances IL-2 production and mitogenic response of peripheral blood mononuclear cells from young and old subjects, J. Nutr., 124, 655, 1994.
124. Gmiinder, H., Roth, S., Eck, H.P., Gallas, H., Mihm, S., and Droge, W., Interleukin-2 mRNA expression, lymphokine production and DNA synthesis in glutathione depleted T cells, Cell. Immunol.,130, 520, 1990.
125. Roth, S., and Droge, W., Regulation of interleukin-2 production, interleukin-2 mRNA expression and intracellular glutathione levels in ex vivo derived T lymphocytes by lactate, Eur. J. Immunol.,21, 1933, 1991.
126. Schreck, R., Rieber, P., and Baeuerle, P.A., Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kB transcription factor and HIV-1, EMBO J.,10, 2247, 1991.
127. Naumann, M. and Scheidereit, C., Activation of NF-kB in vivo is regulated by multiple phosphorylations, EMBO J., 13, 4597, 1994.
128. Muroi, M., Muroi, Y., and Suzuki, T., The binding of immobilized IgG2a to Fcgamma2a receptor activates NF-kB via reactive oxygen intermediates and tumor necrosis factor-α, J. Biol. Chem.,48, 30561, 1994.
129. Flescher, E., Ledbetter, J.A., Schieven, G.L., Velaroch, N., Fossum, D., Dang, H., Ogawa, N., and Talal, N., Longitudinal exposure of human T lymphocytes to weak oxidative stress suppresses transmembrane and nuclear signal transduction, J. Immunol,153, 4880, 1994.
130. Anderson, M.T., Staal, F.J.T., Gitler, C., Herzenberg, L.A., and Herzenberg, L., Separation of oxidant-initiated and redox-regulated steps in the NF-kB signal transduction pathway, Proc. Natl. Acad. Sci. U.S.A.,91, 11527, 1994.
131. Pace, G. W. and Leaf, C.D., The role of oxidative stress in HIV disease, Free Radical Biol. Med.,19, 523, 1995.
132. Dypbukt, J.M., Ankarcrona, M., Burkitt, M., Sjoholm, A., Strom, K., Orrenius, S., and Nicotera, P., Different prooxidant levels stimulate growth, trigger apoptosis or produce necrosis of insulin-secreting RINm5F cells, J. Biol. Chem.,269, 30553, 1994.
133. Fauci, A.S., Multifactorial nature of human immunodeficiency virus disease — implications for therapy, Science,262, 1011, 1993.
134. Ameisen, J.D., Estaquier, J., and Idziorek, T., From AIDS to parasite infection: pathogen-mediated subversion of programmed cell death as a mechanism for immune dysregulation, Immunol. Rev.,142, 9, 1994.
135. Estaquier, J., Idziorek, T., Debels, F., Barresinoussi, F., Hurtel, B., Aubertin, A.M., Venet, A., Mehtali, M., Muchmore, E., Michel, P., Mouton, Y., Girard, M., and Ameisen, J.C., Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections, Proc. Natl. Acad. Sci. U.S.A.,91, 9431, 1994.
136. Pantaleo, G. and Fauci, A.S., Apoptosis in HIV infection, Nature Med.1, 118, 1995.
137. Roederer, M., Dubs, J.G., Anderson, M.T., Raju, P.A., and Herzenberg, L.A., CD8 naive T cell counts decrease progressively in HIV-infected adults, J. Clin. Invest.,95, 2061, 1995.
138. Walker, R.E., Lane, H.C., Boenning, C.M., and Fauci, A.S., The safety, pharmacokinetics, and antiviral activity of N-acetylcysteine in HIV-infected individuals, J. Cell. Biochetn.,16, 89, 1992.
139. Gougeon, M.L., Lecoeur, H., Dulioust, A., Enouf, M.G., Crouvoisier, M., Goujard, C., Debord, T., and Montagnier, L., Programmed cell death in peripheral lymphocytes from HIV-infected persons — increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression, J. Immunol.,156, 3509, 1996.
140. Sarafian, T.A. and Bredesen, D.E., Invited commentary: is apoptosis mediated by reactive oxygen species?Free Radical Res.,21, 1, 1994.
141. Wong, G.H.W. and Goeddel, D.V., Fas antigen and P55 TNF receptor signal apoptosis through distinct pathways, J. Immunol.,152, 1751, 1994.
142. Kohno, T., Yamada, Y., Hata, T., Mori, H., Yamamura, M., Tomonaga, M., Urata, Y., Goto, S., and Kondo, T., Relation of oxidative stress and glutathione synthesis to CD95(Fas/APO-l) -mediated apoptosis of adult T cell leukemia cells, J. Immunol,156, 4722, 1996.
143. Henkart, P.A. and Grinstein, S., Apoptosis: mitochondria resurrected? J. Exp. Med.,183, 1293, 1996.
144. Korsmeyer, S.J., Bcl-2 initiates a new category of oncogenes: regulators of cell death, Blood,80, 879, 1992.
145. Itoh, N., Tsujimoto, Y., and Nagata, S., Effects of bcl-2 on Fas antigen-mediated cell death, J. Immunol.,151, 621, 1993.
146. Hockenbery, D.M., Oltvai, Z.N., Yin, X.M., Milliman, C.L., and Korsmeyer, S.J., Bcl-2 functions in an antioxidant pathway to prevent apoptosis, Cell,75, 241, 1993.
147. Malorni, W., Rivabene, R., Santini, M.T., and Donelli, G., N-acetylcysteine inhibits apoptosis and decreases viral particles in HIV-chronicaly infected U937 cells, FEBS Lett.,327, 75, 1993.
148. Jacobson, M.D. and Raff, M.C., Programmed cell death and Bcl-2 protection in very low oxygen, Nature,374, 814, 1995.
149. Shimizu, S., Eguchi, Y., Kosaka, H., Kamiike, W., Matsuda, H., and Tsujimoto, Y., Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL, Nature,374, 811, 1995.
150. Katsikis, P.D., Wunderlich, E.S., Smith, C.A., and Herzenberg, L.A., Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals, J. Exp. Med.,181, 2029, 1995.
151. Hug, H., Enari, M., and Nagata, S., No requirement of reactive oxygen intermediates in Fas-mediated apoptosis, FEBS Lett.,351, 311, 1994.
152. Chiba, T., Takahashi, S., Sato, N., Ishii, S., and Kikuchi, K., Fas-mediated apoptosis is modulated by intracellular glutathione in human T cells, Eur. J. Immunol.,26, 1164, 1996.
153. van den Dobblesteen, D.J., Nobel, C.S.I., Schlegel, J., Cotgreave, I. A., Orrenius, S., and Slater, A.F.G., Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-fas/APO-1 antibody, J. Biol. Client.,271,15420,1996.
154. Finkel, T.H., Tudorwilliams, G., Banda, N.K., Cotton, M.F., Curiel, T., Monks, C., Baba, T.W., Ruprecht, R.M., and Kupfer, A., Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes, Nature Med.,1, 129, 1995.
155. Wei, X., Ghosh, S.K., Taylor, M.E., Johnson, V.A., Emini, E.A., Deutsch, P., Lifson, J.D., Bonhoeffer, S., Nowak, M.A., Hahn, B.H., Saag, M.S., and Shaw, G.M., Viral dynamics in human immunodeficiency virus type 1 infection, Nature,373, 117, 1995.
156. Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M., and Markowitz, M., Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection, Nature,373, 123, 1995.
157. Coffin, J.M., HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy, Science,267, 483, 1994.
158. Levy, J.A., Pathogenesis of human immunodeficiency virus infection, Microbiol. Rev.,57, 183, 1993.
159. Matsuyama, T., Kobayashi, N., and Yamamoto, N., Cytokines and HIV infection — is AIDS a tumor necrosis factor disease, AIDS,5, 1405, 1991.
160. Israel, N., Gougerotpocidalo, M.A., Aillet, F., and Virelizier, J.L., Redox status of cells influences constitutive or induced NF-kB translocation and HIV long terminal repeat activity in human T-cell and monocytic cell lines, J. Immunol., 149, 3386, 1992.
161. Simon, G., Moog, C., and Obert, G., Valproic acid reduces the intracellular level of glutathione and stimulates human immunodeficiency virus, Chem-Biol. Interact.,91, 111, 1994.
162. Kalebic, T., Kinter, A., Poli, G., Anderson, M.E., Meister, A., and Fauci, A.S., Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine, Proc. Natl. Acad. Sci. U.S.A.,88, 986, 1991.
163. Bergamini, A., Capozzi, M., Ghibelli, L., Dini, L., Salanitro, A., Milanese, G., Wagner, T., Beninati, S., Pesce, C.D., Amici, C., and Rocchi, G., Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells, J. Clin. Invest.,93, 2251, 1994.
164. Harakeh, S. and Jariwalla, R.J., Comparative study of the anti-HIV activities of ascorbate and thiol-containing reducing agents in chronically HIV-infected cells, Am. J. Clin. Nutr.,54, S1231, 1991.
165. Ho W.-Z. and Douglas, S.D., Glutathione and normal-acetylcysteine suppression of human immunodeficiency virus replication in human monocyte/macrophages in vitro, AIDS Res. Hum. Retrovirus.,8, 1249, 1992.
166. Roederer, M., Staal, F.J.T., Raju, P.A., Ela, S.W., Herzenberg, L.A., and Herzenberg, L., Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine, Proc Natl. Acad. Sci. U.S.A.,87, 4884, 1990.
167. Raju, P.A., Herzenberg, L.A., and Roederer, M., Glutathione precursor and antioxidant activities of N-acetylcysteine and oxothiazolidine carboxylate compared in in vitro studies of HIV replication, AIDS Res. Hum. Retrovirus., 10, 961, 1994.
168. Lioy, J., Ho, W.-Z., Cutilli, J.R., Polin, R.A., and Douglas, S.D., Thiol suppression of human immunodeficiency virus type-1 replication in primary cord blood monocyte-derived macrophages in vitro, J. Clin. Invest.,91, 495, 1993.
169. Djurhuus, R., Svardal, A.M., Mansoor, M.A., and Ueland, P.M., Modulation of glutathione content and the effect of methionine auxotrophy and cellular distribution of homocysteine and cysteine in mouse cell lines, Carcinogenesis, 12, 241, 1991.
170. Prochaska, H.J., Yeh, Y., Baron, P., and Polsky, B., Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication, Proc. Natl. Acad. Sci. U.S.A., 90, 3953, 1993.
171. Prochaska, H.J., Chavan, S.J., Baron, P., and Polsky, B., Oltipraz, a novel inhibitor of human immunodeficiency virus type 1 (HIV-1) replication, J. Cell Biochem.,117, 1995.
172. Mansoor, M.A., Ueland, P.M., Aarsland, A., and Svardal, A.M., Redox status and protein binding of plasma homocysteine and other aminothiols in patients with homocystinuria, Metabolism,42, 1481, 1993.
173. Mansoor, M.A., Ueland, P.M., and Svardal, A.M., Redox status and protein binding of plasma homocysteine and other aminothiols in patients with hy-perhomocysteinemia due to cobalamin deficiency, Am. J. Clin. Nutr.,59, 631, 1994.
174. Mansoor, M.A., Guttormsen, A.B., Fiskerstrand, T., Refsum, H., Ueland, P.M., and Svardal, A.M., Redox status and protein binding of plasma aminothiols during the transient hyperhomocysteinemia that follows homocysteine ad-minstration, Clin. Chem.,39, 980, 1993.
175. Mansoor, M.A., Svardal, A.M., Schneede, J., and Ueland, P.M., Dynamic relation between reduced, oxidized, and protein-bound homocysteine and other thiol components in plasma during methionine loading in healthy men, Clin. Chem.,38, 1316, 1992.
176. Graham, N.M., Sorensen, D., Odaka, N., Brookmeyer, R., Chan, D., Willett, W.C., Morris, J.S., and Saah, A.J., Relationship of serum copper and zinc levels to HIV-1 seropositivity and progression to AIDS, J. Acq. Immun. Defic, Synd. Hum. R.,4, 976, 1991.
177. Beach, R.S., Mantero-Atienza, E., Shor-Posner, G., Javier, J.J., Szapocznik, J., Morgan, R., Säuberlich, H.E., Cornwell, P.E., Eisdort'er, C., and Baum, M.K., Specific nutrient abnormalities in asymptomatic HIV-1 infection, AIDS,6, 701, 1992.
178. Schreck, R.., Meier, B., Mannei, D.N., Dröge, W., and Baeuerle, P.A., Dithio-carbamates as potent inhibitors of nuclear factor kappaB activation in intact cells, J. Exp. Med.,175, 1181, 1992.
179. Rule, S.A.J., Hooker, M., Costello, C., Luck, W., and Hoffbrand, A.V., Serum vitamin B-12 and transcobalamin levels in early HIV disease, Am. J. Hematol, 47, 167, 1994.
180. Beach, R.S., Morgan, R., Wilkie, F., Mantero-Atienza, E., Blaney, N., Shor-Posner, G., Lu, Y., Eisdorfer, C., and Baum, M.K., Plasma vitamin B12 level as a potential cofactor in studies of human immunodeficiency viurs type 1-related cognitive changes, Arch. Neurol,49, 501, 1992.
181. Helbling, B., Von Overbeck, J., and Lauterburg, B.H., Decreased synthesis of glutathione in patients with AIDS, Eur. J. Clin. Invest.,24, A38, 1994.
182. Markowitz, M., Saag, M., Powderly, W.G., Hurley, A.M., Hsu, A., Valdes, J.M., Henry, D., Sattler, F., Lamarca, A., Leonard, J.M., and Ho, D.D., A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection, N. Engl. J. Med.,333, 1534, 1995.
183. Collier, A.C., Coombs, R.W., Schoenfeld, D.A., Bassett, R.L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V.J., Friedman, H.M., Merigan, T.C., Reichman, R.C., Hooper, C., and Corey, L., Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitab-ine, N. Engl. J. Med.,334, 1011, 1996.
184. Dalgleish, A.G., The immune response to HIV: potential for immunotherapy?Immunol Today,16, 356, 1995.
185. Aruoma, O.I., Halliwell, B., Hoey, B.D., and Butler, J., The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid, Free Radical Biol. Med.,6, 593, 1989.
186. Burgunder, J.M., Varriale, A., and Lauterburg, B.H., Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration, Eur. J. Clin. Pharmacol,36, 127, 1989.
187. Smilkstein, M.J., Knapp, G.L., Kulig, K.W., and Rumack, B.H., Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose, N. Engl. J. Med., 319, 1557, 1988.
188. Meister, A., Anderson, M.E., and Hwang, O., Intracellular cysteine and glutathione delivery systems, J. Am. Coll. Nutr.,5, 137, 1986.
189. Meyer, A., Buhl, R., Kampf, S., and Magnussen, H., Intravenous N-acetylcys-teine and lung glutathione of patients with pulmonary fibrosis and normals, Am. J. Respir. Crit. Care Med.,152, 1055, 1995.
190. Holdiness, M.R., Clinical pharmacokinetics of N-acetylcysteine, Clin. Pharma-cokinet., 20,123, 1991.
191. Mihm, S., Ennen, J., Pessara, U., Kurth, R., and Dröge, W., Inhibition of HIV-1 replication and NF-kB activity by cysteine and cysteine derivatives, AIDS, 5, 497, 1991.
192. Roberts, R.L., Aroda, V.R., and Ank, B.J., N-acetylcysteine enhances antibody-dependent cellular cytotoxicity in neutrophils and mononuclear cells from healthy adults and human immunodeficiency virus-infected patients, J. Infect. Dis.,172, 1492, 1995.
193. Sandstrom, P.A., Mannie, M.D., and Buttke, T.M., Inhibition of activation-induced death in T cell hybridomas by thiol antioxidants — oxidative stress as a mediator of apoptosis, J. Leukocyte Biol.,55, 221, 1994.
194. Cossarizza, A., Franceschi, C., Monti, D., Salvioli, S., Bellesia, E., Rivabene, R., Biondo, L., Rainaldi, G., Tinari, A., and Malorni, W., Protective effect of N-acetylcysteine in tumor necrosis factor-alpha-induced apoptosis in U937 cells: the role of mitochondra, Exp. Cell Res.,220, 232, 1995.
195. Malorni, W., Rivabene, R., Santini, M.T., Rainaldi, G., and Donelli, G., N-acetylcysteine prevents TNF-induced mitochondrial damage, apoptosis and viral particle production in HIV-infected U937 cells, Redox. Rep.,1, 57, 1994.
196. Jones, D.P., Maellaro, E., Jiang, S.N., Slater, A.F.G., and Orrenius, S., Effects of N-acetyl-L-cysteine on T-cell apoptosis are not mediated by increased cellular glutathione, Immunol. Lett.,45, 205, 1995.
197. Witschi, A., Junker, E., Schranz, C., Speck, R.F., and Lauterburg, B.H., Supplementation of N-acetylcysteine fails to increase glutathione in lymphocytes and plasma of patients with AIDS, AIDS Res. Hum. Retrovirus.,11, 141, 1995.
198. Helbling, B., VonOverbeck, J., and Lauterburg, B.H., Decreased release of glutathione into the systemic circulation of patients with HIV infection, Eur. J. Clin. Invest.,26, 38, 1996.
199. Porta, P., Aebi, S., Summer, K., and Lauterburg, B.H., L-2-oxothiazolidine-4-carboxylic acid, a cysteine prodrug: pharmacokinetics and effects on thiols in plasma and lymphocytes in human, J. Pharmacol. Exp. Ther.,257, 331, 1991.
200. Kalayjian, R.C., Skowron, G., Emgushov R.T., Chance, M, Spell, S.A., Borum, P.R., Webb, L.S., Mayer, K.H., Jackson, J.B., Yenlieberman, B., Story, K.O., Rowe, W.B., Thompson, K., Goldberg, D., Trimbo, S., and Lederman, M.M., A phase I/II trial of intravenous L-2-oxothiazolidine-4-carboxylic acid (procysteine) in asymptomatic HIV-infected subjects, J. Acq. Immun. Defic. Synd. Hum. R.,7, 369, 1994.
201. Ho W.-Z., Zhu, X.-H., Song, L., Lee, H.-R., Cutilli, J.R., and Douglas, S.D., Cystamine inhibits HIV type 1 replication in cells of monocyte/macrophage and T cell lineages, AIDS Res. Hum. Retrovirus.,11, 451, 1995.
202. Markello, T.C., Bemardini, M.E., and Gahl, W.A., Improved renal function in children with cystinosis treated with cysteamine, N. Engl. J. Med.,328, 1157, 1993.
203. Bergamini, A., Ventura, L., Mancino, G., Capozzi, M., Placido, R., Salanitro, A., Cappannoli, L., Faggioli, E., Stoler, A., and Rocchi, G., In vitro inhibition of the replication of human immunodeficiency virus type 1 by β-mercapto-ethylamine (cysteamine), J. Infect. Dis.,174, 214, 1996.
204. Fuchs, J., Schofer, H., Ochsendorf, F., Janka, S., Milbradt, R., Buhl, R., Unkelbach, U., Freisieben, H.J., Oster, O., Siems, W., Grune, T., and Esterbauer, H., Antioxidants and peroxidation products in the blood of HIV-1 infected patients with HIV associated skin diseases, Eur. J. Dermatol,4, 148, 1994.
205. Sappey, C., Leclercq, P., Coudray, C., Faure, P., Micoud, M., and Favier, A., Vitamin, trace element and peroxide status in FIIV seropositive patients: asymptomatic patients present a severe beta-carotene deficiency, Clin. Chim. Acta,230, 35, 1994.
206. Allavena, C., Dousset, B., May, T., Dubois, F., Canton, P., and Belleville, F., Relationship of trace element, immunological markers, and HIV-1 infection progression, Biol. Tr. Elem. Res.,47, 133, 1995.
207. Sappey, C., Legrandpoels, S., Bestbelpomme, M., Favier, A., Rentier, B., and Piette, J., Stimulation of glutathione peroxidase activity decreases HIV type 1 activation after oxidative stress, AIDS Res. Hum. Retrovirus.,10, 1451, 1994.
208. Westendorp, M.O., Shatrov, V.A., Schulze-Osthoff, K., Frank, R., Kraft, M., Los, M., Krammer, P.H., Droge, W., and Lehmann, V., HIV-1 tat potentiates TNF-induced NF-kB activation and cytotoxicity by altering the cellular redox state, EMBO J., 14, 546, 1995.
209. Tramontana, J.M., Utaipat, U., Molloy, A., Akarasewi, P., Burroughs, M., Makonkawkeyoon, S., Johnson, B., Klausner, J.D., Rom, W., and Kaplan, G., Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis, Mol. Med.,1, 384, 1995.
210. Klausner, J.D., Makonkawkeyoon, S., Akarasewi, P., Nakata, K., Kasinrerk, W., Corral, L., Dewar, R.L., Lane, H.C., Freedman, V.H., and Kaplan, G., The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M-tuberculosis infection, J. Acq. hnmun. Defic. Synd. Hum. R. 11, 247, 1996.
211. Kruse, A., Rieneck, K., Kappel, M., Orholm, M., Bruunsgaard, H., Ullum, H., Skinhoj, P., and Pedersen, B.K., Pentoxifylline therapy in HIV seropositive subjects with elevated TNF, Immunopharmacology,31, 85, 1995.
212. Dezube, B.J., Pardee, A.B., Chapman, B., Beckett, L.A., Korvick, J.A., Novick, W.J., Chiurco, J., Kasdan, P., Ahlers, C.M., Ecto, L.T., and Crumpacker, C.S., Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS, J. Acq. Imtnun. Defic. Synd. Hum. R.,6, 787, 1993.
213. Dezube, B.J., Lederman, M.M., Spritzler, J.G., Chapman, B., Korvick, J.A., Flexner, C., Dando, S., Mattiacci, M.R., Ahlers, C.M., Zhang, L., Novick, W.J., Kasdan, P., Fahey, J.L., Pardee, A.B., and Crumpacker, C.S., High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production, J. Infect. Dis.,171, 1628, 1995.
214. Suzuki, Y.J. and Packer, L., Inhibition of NF-kB activation by vitamin E derivatives, Biochem. Biophys. Res. Commute,193, 277, 1993.
215. Suzuki, Y.J., Aggarwal, B.B., and Packer, L., Alpha-lipoic acid is a potent inhibitor of NF-kB activation in human T cells, Biochem. Biophys. Res. Commun., 189, 1709, 1992.
216. Harakeh, S., Jariwalla, R.J., and Pauling, L., Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells, Proc. Natl. Acad. Sci U.S.A.,87, 7245, 1990.
217. Harakeh, S. and Jariwalla, R.J., Ascorbate effect on cytokine stimulation of HIV production, Nutrition,11, 684, 1995.
218. Sauberlich, H.E., Pharmacology of vitamin C, Annu. Rev. Nutr.,14, 371, 1994.